LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Subscribe To Our Newsletter & Stay Updated
